BioCentury
ARTICLE | Company News

Korea approves Medipost's mesenchymal stem cell therapy

February 23, 2012 12:50 AM UTC

Medipost (KOSDAQ:078160) said the Korean FDA approved Cartistem to treat osteoarthritis. Cartistem consists of allogeneic mesenchymal stem cells from umbilical cord blood. The product is marketed in K...